First, we aim to investigate whether 12 weekly recombinant human EPO infusions ameliorate cognitive impairments in first-degree relatives without psychotic or mood disorders to patients with BD, recurrent UD, or schizophrenia (sub-study 1). Here, EPO is linked to Behcet disease.